Novartis's MS Treatment Fails in Trial

Novartis said a late-stage study showed little difference between the Swiss pharmaceutical group’s Gilenya drug and a placebo for treating a difficult form of multiple sclerosis.



from WSJ.com: US Business http://ift.tt/1vzY1TK

via IFTTT